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Obstructive sleep apnea (OSA) is a common sleep breathing disorder associated
with an increased risk of cardiovascular and cerebrovascular diseases and mortality.
Although OSA is fairly heritable (∼40%), there have been only few studies looking
into the genetics of OSA. In the present study, we aimed to identify genetic variants
associated with symptoms of sleep apnea by performing a whole-exome sequence
meta-analysis of symptoms of sleep apnea in 1,475 individuals of European descent.
We identified 17 rare genetic variants with at least suggestive evidence of significance.
Replication in an independent dataset confirmed the association of a rare genetic
variant (rs2229918; minor allele frequency = 0.3%) with symptoms of sleep apnea
(p-valuemeta = 6.98× 10
−9, βmeta = 0.99). Rs2229918 overlaps with the 3
′ untranslated
regions of ERCC1 and CD3EAP genes on chromosome 19q13. Both genes are
expressed in tissues in the neck area, such as the tongue, muscles, cartilage and the
trachea. Further,CD3EAP is localized in the nucleus andmitochondria and involved in the
tumor necrosis factor-alpha/nuclear factor kappa B signaling pathway. Our results and
biological functions ofCD3EAP/ERCC1 genes suggest that the 19q13 locus is interesting
for further OSA research.
Keywords: sleep apnea syndromes, sleep, genetics, exome, sequence analysis, ERCC1, CD3EAP
Abbreviations: BMI, body mass index; BWA, Burrows Wheeler Aligner; EMC, Erasmus Medical Center; ERF, Erasmus
Rucphen Family; FHS, FraminghamHeart Study; GATK, GenomeAnalysis Toolkit; GRCh37, Genome Reference Consortium
Human Build 37; GWAS, genome wide association study; Hg19, human genome build 19; HWE, Hardy-Weinberg
equilibrium;MAF, minor allele frequency; OSA, obstructive sleep apnea; PSQI, Pittsburgh Sleep Quality Index; RS, Rotterdam
Study; SNV, single nucleotide variant; UBTF, upstream binding transcription factor; UTR, untranslated region; WES,
whole-exome sequence.
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INTRODUCTION
Sleep is a complex and essential biological process that has been
conserved across diverse animal species throughout evolution
(Rechtschaffen, 1998). Although normal healthy sleep highly
varies within and between adults (Van Dongen et al., 2005;
Knutson et al., 2007; Mezick et al., 2009), it has to consist of
adequate duration, good quality, proper timing and regularity,
and the absence of sleep disturbances or disorders (Consensus
Conference Panel et al., 2015). Several large epidemiological
studies have shown that short or disturbed sleep is associated with
various cognitive (Pilcher and Huffcutt, 1996; Yaffe et al., 2014),
psychiatric (Lovato and Gradisar, 2014; Peters van Neijenhof
et al., 2016; Cosgrave et al., in press) and health consequences
e.g., diabetes mellitus (Gottlieb et al., 2005; Yaggi et al., 2006),
activation of pro-inflammatory pathways (Patel et al., 2009), and
cardiovascular diseases (Hoevenaar-Blom et al., 2011). One of the
most common causes of short and disturbed sleep is sleep apnea.
Sleep apnea is a highly prevalent (Peppard et al., 2013) sleep
breathing disorder, with obstructive sleep apnea (OSA) as the
most common type (Mehra et al., 2007). OSA affects up to
38% of the general adult population (Senaratna et al., 2016) and
untreated OSA has been associated with severe health problems
(Young et al., 2002a) such as hypertension (Peppard et al., 2000;
Pedrosa et al., 2011), cardiovascular disease (Shamsuzzaman
et al., 2003; Marin et al., 2005; Gottlieb et al., 2010), stroke
(Yaggi et al., 2005), type 2 diabetes (Shaw et al., 2008; Aurora
and Punjabi, 2013; Kendzerska et al., 2014), impaired cognitive
function (Kim et al., 1997; Yaffe et al., 2011), depression (Peppard
et al., 2006), and increasedmortality (Marshall et al., 2008; Young
et al., 2008; Punjabi et al., 2009). The main characteristic of OSA
is the partial or complete obstruction of the upper airways during
sleep, causing oxyhemoglobin desaturations and arousals from
sleep. This leads to sleep fragmentation and decreased periods
of slow wave and REM sleep (McNicholas, 2008; American
Academy of Sleep Medicine, 2014). Consequently, the two most
common signs and symptoms of OSA are snoring and excessive
daytime sleepiness (Gottlieb et al., 1999) where the latter can
result in personal and occupational problems, and an increased
risk of traffic and work-related accidents (Young et al., 2002a;
McNicholas, 2008; American Academy of Sleep Medicine, 2014).
OSA is a complex trait influenced by both environment and
genetics (Redline et al., 1995; Redline and Tishler, 2000) with
obesity, age, and sex as most important risk factors (Redline et al.,
1994; Bixler et al., 2001; Young et al., 2002a,b, 2004; Peppard
et al., 2013). About 40% of the variance in apneic activity can be
explained by genetic factors (Redline et al., 1995). At least half of
the genetic contribution to sleep apnea acts through mechanisms
independent of obesity (Patel et al., 2008). Previous genetic
studies have focused on several candidate genes for breathing
disorders, where the most studied genes are the angiotensin-
converting enzyme gene (ACE) (Lin et al., 2004; Bostrom et al.,
2007; Patel et al., 2007); apolipoprotein, allele E4 (APOE ǫ4)
(Kadotani et al., 2001; Gottlieb et al., 2004); serotonin receptors
and transporters genes (5-HT2A, 5-HT2C, 5-HTT) (Sakai et al.,
2005; Ylmaz et al., 2005; Bayazit et al., 2006; Larkin et al.,
2010; Qin et al., 2014); adrenergic receptors (ADRB2/3) (Mills
et al., 1995; Grote et al., 2000); and tumor necrosis factor (TNF)
(Riha et al., 2005; Popko et al., 2008; Bhushan et al., 2009).
However, the results of these studies have been inconsistent or
have yet to be confirmed (Sleiman and Hakonarson, 2011). Using
linkage analysis, a method to identify the chromosomal location
of the disease influencing genes, two regions on chromosome
2p16 and 19q13 were found to be suggestively linked with OSA
independent of obesity (Palmer et al., 2003). Genome wide
association studies (GWASs) could provide more information
on common variants involved in the pathogenesis of OSA. Until
now only a few GWASs have been reported for OSA. Loci in
GPR83 and C6ORF183/CCDC162Pwere found to be significantly
associated with OSA (Cade et al., 2016), and a locus in the
neuregulin-1 (NRG1) gene was suggestively implicated (Baik
et al., 2015). Two other studies used customized or targeted
genotyping arrays and identified loci in PPARGC1B (Kripke et al.,
2015), PTGER3 (Patel et al., 2012), PLEK (Patel et al., 2012), and
LPAR1 (Patel et al., 2012) to be associated with OSA. However,
most of these findings were not replicated. Consequently, the
genetic architecture of OSA remains largely unexplored.
In the present study we aimed to identify genetic variants
associated with symptoms of sleep apnea, assessed using the
Pittsburgh Sleep Quality Index (PSQI). We performed a GWAS
using whole-exome sequence (WES) data of 1,475 individuals
from two Dutch studies. Subsequently, we replicated our findings
in an independent sample.
MATERIALS AND METHODS
Study Populations
Discovery Cohorts
The discovery sample consists of participants from two cohorts
including the Erasmus Rucphen Family (ERF) study and the
Rotterdam Study (RS) from The Netherlands.
ERF is a family-based study that includes inhabitants of
a genetically isolated community in the Southwest of the
Netherlands, ascertained as part of the Genetic Research in
Isolated Population program. The ERF cohort includes ∼3,000
living descendants of 22 founder couples, who had at least
six children baptized in the community church. Individuals
who were 18 years or older were invited to participate in
the study. Data was collected between 2002 and 2005 (Pardo
et al., 2005). The study was approved by the Medical Ethics
Committee of the Erasmus Medical Center (EMC), Rotterdam,
The Netherlands. All participants provided written informed
consent and all investigations were carried out in accordance with
the Declaration of Helsinki.
RS is a prospective cohort study ongoing since 1990, which
aims to investigate determinants of disease occurrence and
progression in the elderly (Hofman et al., 2015). Initially, the RS
included 7,983 individuals of 55 years of age or over, living in the
well-defined Ommoord district in Rotterdam, The Netherlands.
All participants were examined at baseline by an at home
interview and an extensive set of examinations in the research
facility in Ommoord. The RS was approved by theMedical Ethics
Committee of the EMC and by the Ministry of Health, Welfare
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and Sport of the Netherlands. All participants provided written
informed consent to participate in the study. All investigations
were carried out in accordance with the Declaration of Helsinki.
Study participants from ERF and RS were assessed for sleep
phenotypes using a self-administered questionnaire including
questions from the PSQI (Buysse et al., 1989). The PSQI has
been specifically designed to measure sleep quality and sleep
disturbances over a 1-month time interval. Symptoms of sleep
apnea were assessed by asking the participants “How often did
you or your partner notice long pauses between breaths while
asleep?” Answers were provided on a categorical scale ranging
from 1 to 4 (1. not during the past month; 2. less than once per
week; 3. once or twice per week; 4. more than twice per week).
Symptoms of sleep apnea were assessed in 1,366 ERF participants
and 2,660 RS participants, where for the latter data of the fourth
visit was used as it had the largest participation.
Replication Cohort
The replication sample included participants from the offspring
cohort of the population-based prospective Framingham Heart
Study (FHS) (Dawber et al., 1951). The offspring cohort was
recruited between 1971 and 1975, including 5,124 offspring of the
original FHS cohort and their spouses (Kannel et al., 1979). The
study was approved by the Institutional Review Board for Human
Research of the Boston University Medical Center, Boston, MA,
USA. Each participant provided written informed consent.
FHS has collected sleep data using the Sleep Heart Health
Study sleep habits questionnaire (Quan et al., 1997). Symptoms
of sleep apnea scores were constructed as a combination of the
following questions: “A. Are there times when you stop breathing
during your sleep?” with answers “yes”, ”no”, “I don’t know” and
“B. If yes to question A: How often do you have times when you
stop breathing during your sleep?”. Answers to question B were
provided on a categorical scale ranging from 1 to 5 (1. Rarely,
less than one night per week; 2. Sometimes, one or two nights
per week; 3. Frequently, three to five nights per week; 4. always
or almost always, six or seven nights per week; 5. I don’t know).
Individuals with answers “I don’t know” were excluded, since this
option is not available in the PSQI. The constructed symptoms
of sleep apnea score had answers ranging from 1 to 4, matching
the PSQI: 1. not during the past month (A2); 2. less than once per
week (A1 and B1); 3. once or twice per week (A1 and B2); 4. more
than twice per week (A1 and B3 or A1 and B4).
Sequencing and Quality Control
Discovery Cohorts
In ERF Genomic DNA was extracted from peripheral venous
blood utilizing the salting out method (Miller et al., 1988).
Exomes of 1,336 ERF participants were sequenced at the Erasmus
Center for Biomics of the Cell Biology department of the
EMC, The Netherlands, using the Agilent V4 capture kit on
an Illumina HiSeq2000 sequencing machine with the TruSeq
Version 3 protocol (Amin et al., 2016b). The sequence reads
were aligned to the human genome build 19 (hg19) using
Burrows Wheeler Aligner (BWA) (Li and Durbin, 2009) and
the NARWHAL pipeline (Brouwer et al., 2012). Aligned reads
were further processed using IndelRealigner, MarkDuplicates
and TableRecalibration tools from the Genome Analysis Toolkit
(GATK) (Mckenna et al., 2010), and Picard (http://broadinstitute.
github.io/picard/). Genetic variants were called using the GATK
UnifiedGenotyper tool. Individuals with low concordance to
genotyping array or with a low call rate and low quality variants
(Phred quality score <30, call rate <90%) and out of Hardy-
Weinberg equilibrium (HWE) (p < 10−6), were removed. The
final dataset for ERF included 528,617 single nucleotide variants
(SNVs) in 1,308 individuals (Amin et al., 2016b) of whom 654
individual also had phenotype data on symptoms of sleep apnea
available.
Exomes of 2,628 individuals from the RS population were
sequenced at the Human Genotyping facility of the Internal
Medicine department at the EMC, the Netherlands, to an
average depth of 54x using the Nimblegen SeqCap EZ V2
capture kit on an Illumina Hiseq2000 sequencer using the
TruSeq Version 3 protocol (Amin et al., 2016b). The sequenced
reads were aligned to hg19 using BWA (Li and Durbin, 2009).
Subsequently, the aligned reads were processed further using
Picard’s MarkDuplicates, SAMtools (Li et al., 2009), and GATK
(Mckenna et al., 2010). Genetic variants were called using the
Haplotypecaller from GATK. Samples with low concordance to
genotyping array (<95%), low transition to transversion ratio
(<2.3) and high heterozygote to homozygote ratio (>2.0) were
removed and additionally SNVs with a low call rate (<90%) and
out of HWE (p < 10−8) were also removed from the data. The
final dataset included 600,806 SNVs in 2,356 individuals (Amin
et al., 2016a) of whom 821 individuals also had phenotype data
on symptoms of sleep apnea available.
For both ERF and RS, file handling and formatting was done
using VCFtools (Danecek et al., 2011) and PLINK (Purcell et al.,
2007) (http://pngu.mgh.harvard.edu/purcell/plink/). Annotation
of the variants was performed using SeattleSeq Annotation 138
(http://snp.gs.washington.edu/SeattleSeqAnnotation138/).
Replication Cohort
In FHS exomes of 1,271 participants were sequenced using
Illumina HiSeq2000 and 2500 platforms. DNA samples were
constructed into Illumina paired-end pre-capture libraries
according to the manufacturer’s protocol. For exome capture,
two, four or six pre-capture libraries were pooled together
and hybridized to the HGSC VCRome 2.1 design (Bainbridge
et al., 2011) (42Mb, NimbleGen). After sequencing the HGSC
Mercury analysis pipeline (https://www.hgsc.bcm.edu/content/
mercury) and Illumina CASAVA software were used to perform
sequencing analysis and to de-multiplex the pooled samples.
Sequenced reads were aligned to Genome Reference Consortium
Human Build 37 (GRCh37) using BWA (Li and Durbin, 2009)
producing BAM files (Li et al., 2009). The aligned reads were
recalibrated using GATK (Depristo et al., 2011) together with
BAM sorting, duplicate read marking, and realignment near
insertions or deletions. SNVs, insertions and deletions were
called using Atlas2 (Challis et al., 2012). SNVs were excluded
with low SNV posterior probability (<0.95), low variant read
count (<3), variant read ratio <0.25 or >0.75, strand-bias of
more than 99% variant reads in a single strand direction, or total
coverage <10. Reference calls with <10× coverage were also set
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to missing. Variants were excluded outside exon capture regions
(VCRome 2.1), multi-allelic sites, monomorphic sites, missing
rate >20%, mappability score <0.8, mean depth of coverage
>500, or not fulfilling HWE (p < 5 × 10−6). Samples were
excluded with missingness >20%, less than 6 SD from mean
depth, more than 6 SD for singleton count, or outside of 6 SD for
heterozygous to homozygous ratio or transition to transversion
ratio. Variants were annotated using ANNOVAR (Wang et al.,
2010) and dbNSFP v2.0 (https://sites.google.com/site/jpopgen/
dbNSFP) according to the GRCh37 reference genome and
National Center for Biotechnology Information RefSeq. The final
dataset included 1,749,755 SNVs in 1,271 individuals of whom
472 individuals also had phenotype data on symptoms of sleep
apnea available.
Statistical Analyses
Descriptive analysis was performed using IBM SPSS Statistics
version 21 (IBM Corp. Released 2012. IBM SPSS Statistics
for Windows, Version 21.0. Armonk, NY: IBM Corp.). Study
specific exome analyses and meta-analysis of the individual study
data were performed using the seqMeta v1.5 library of the
R software (http://cran.r-project.org/web/packages/seqMeta/).
Single variant association analysis was performed by assuming
an additive effect. In ERF and FHS a linear mixed effects model
was used adjusting for familial relationships by including the
kinship matrix. To account for population stratification in the
RS, we tested the association of ten principal components with
the phenotype. None of them was significantly associated with
symptoms of sleep apnea and we did not include them in the
analysis. The regression analysis was performed using the four
categories of symptoms of sleep apnea score as a continuous trait,
adjusting for the three main risk factors for OSA; age, sex and
body mass index (BMI) (kg/m2). Meta-analysis was performed
using a fixed effects model. Variants that were present in both
discovery cohorts (ERF and RS, 115,526 variants) were tested for
association, giving a Bonferroni corrected p-value threshold of
4.3 × 10−7. All variants that showed significant or suggestive
(p < 1.0 × 10−6) association signals in the discovery samples,
were tested for replication in FHS. Bonferroni correction was also
applied to correct for multiple testing in the replication stage.
RESULTS
Descriptive statistics of the study populations are presented in
Table 1. The mean age in RS was 75 years (xBMI = 27.4 kg/m
2),
TABLE 1 | Descriptive statistics of the study populations.
ERF RS FHS
N 654 821 472
Age (years), mean ± SD 46.4 ± 13.4 75.0 ± 6.1 59.2 ± 9.4
Male (%) 42.5 46.8 48.5
BMI (kg/m2), mean ± SD 26.7 ± 4.4 27.4 ± 4.0 27.5 ± 4.7
ERF, Erasmus Rucphen Family study; RS, Rotterdam Study; FHS, Framingham Heart
Study; N, number of participants; BMI, body mass index.
where the mean age in ERF was 46 years (xBMI = 26.7 kg/m
2)
and 59 years in FHS (xBMI = 27.5 kg/m
2). The prevalence of
symptoms of sleep apnea was higher in the ERF population,
where 16.8% of the participants reported to have experienced
apneas during the last month, compared to 11.6 and 6.6% of the
RS and FHS participants, respectively (Table 2).
The exome-wide association results and the distribution of the
test statistic (λ= 1.02) are illustrated in Figures 1, 2 respectively.
Significant associations of symptoms of sleep apnea were
observed with six rare variants [minor allele frequency (MAF)
< 1%] (located in ACE, AIFM3, LIPJ, MUC2, AP2A2, SH3BP1)
(Table 3). Suggestive associations of symptoms of sleep apnea
were observed with 11 rare variants (located in KANK2, LCN6,
TRAF3, PLEK, HIF1A, SLC45A3, ERCC1/CD3EAP, MRGPRE,
GRAMD4, TYW5, CST5) (Table 3). Of all 17 variants, only
seven were polymorphic in the replication sample and could be
tested for association (Table 4). Of the six significantly associated
variants, two could be tested for association with symptoms of
sleep apnea in the FHS (located inMUC2 and SH3BP1).
A significant association of symptoms of sleep apnea with
rs2229918, located on chromosome 19q13 in the overlapping 3
′
-
untranslated region (UTR) of the ERRC1 and CD3EAP genes
(Figure 3), was observed in the replication sample (p = 1.84 ×
10−3). Moreover, both the frequency (MAFFHS = 0.3%) and the
effect size of the minor allele (G; βFHS = 0.87) were consistent
with that of the discovery cohorts (MAF = 0.3%, β = 1.07)
suggesting that each copy of the minor allele (G) can result in
a shift to a higher category in self-reported apnea symptoms
(PSQI). Meta-analysing the discovery and replication cohorts
yielded an increased significance of the association of rs2229918
with symptoms of sleep apnea (p= 6.98× 10−9, β = 0.99).
DISCUSSION
This study aimed at identifying genetic variants associated with
symptoms of sleep apnea by performing a meta-analysis of
WES data. We identified a rare genetic variant (MAF = 0.3%),
rs2229918, located in the shared 3′-UTR region of the ERCC1 and
CD3EAP genes with a large effect on symptoms of sleep apnea.
We show significant replication of rs2229918 in an independent
sample.
The CD3EAP gene is located in antisense orientation to
ERCC1 where the 3′-UTRs of both genes overlap. This type
TABLE 2 | Answers to the sleep apnea question for the discovery and replication
populations.
ERF (%) RS (%) FHS (%)
How often did you
or your partner
notice long pauses
between breaths
while asleep (a
so-called sleep
apnea)?
Not during the last
month
544 (83.2) 726 (88.4) 441 (93.4)
Less than once a week 48 (7.3) 44 (5.4) 16 (3.4)
Once or twice a week 32 (4.9) 32 (3.9) 6 (1.3)
More than twice a week 30 (4.6) 19 (2.3) 9 (1.9)
Total 654 821 472
ERF, Erasmus Rucphen Family study; RS, Rotterdam Study; FHS, Framingham Heart
Study.
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FIGURE 1 | Manhattan plot of the meta-analysis of symptoms of sleep apnea. This plot shows −log10 transformed p-values (y-axis) for all SNPs present in the
meta-analysis according to their position on each chromosome (x-axis). The red dashed line represents the Bonferroni corrected p-value threshold for significance (p
< 4.3 × 10−7) and the blue dashed line indicates the threshold for suggestive associations (p < 1.0 × 10−6).
FIGURE 2 | Quantile-Quantile plot of the meta-analysis of symptoms of sleep
apnea. The QQ-plot shows the observed p-values plotted on the y-axis
against the expected values of the test statistics on the x-axis (X2-distribution).
The red line shows the distribution under the null hypothesis.
of 3′-UTR overlap is conserved in mice and yeast suggesting
an important biological function (OMIM #107325). 3′-UTRs
can be highly enriched for regulatory elements such as binding
sites for regulatory proteins and microRNAs and therefore are
most likely involved in post-transcriptional regulation (Xie et al.,
2005). ERCC1 encodes Excision Repair Cross-Complementation
Group 1, a protein functioning in the nucleotide excision repair
pathway and needed for the repair of DNA lesions but also
involved in recombinational DNA repair and the repair of inter-
strand crosslinks (Stelzer et al., 2016). Mutations in ERCC1
have been linked to cerebro-oculo-facio-skeletal syndrome 4,
a severe autosomal recessive disorder characterized by growth
retardation, dysmorphic facial features, arthrogryposis, and
neurologic abnormalities (OMIM #610758). CD3EAP is a
component of RNA polymerase I which synthesizes ribosomal
RNA precursors and is involved in poly(A) RNA binding and
DNA-directed RNA polymerase activity (Stelzer et al., 2016).
CD3EAP is localized in the nucleus and mitochondria and has
two isoforms, isoform 1 is involved in UBTF-activated (Upstream
Binding Transcription Factor, RNA Polymerase 1) transcription,
while isoform 2 is a component of preformed T-cell receptor
complex. CD3EAP is involved in multiple pathways including
rRNA expression and RNA Polymerase 1 transcription related
pathways; RNA polymerase I promotor escape and transcription;
gene expression; and the TNF-alpha/NF-kB signaling pathway
(Stelzer et al., 2016). Previous genetic studies have associated NF-
kB-dependent genes, especially TNF-α, with OSA (Riha et al.,
2005; Ryan et al., 2006; Popko et al., 2008; Bhushan et al., 2009).
Moreover, NF-kB is thought to play a key role in mediation
of the inflammatory and cardiovascular consequences of OSA
(Ryan et al., 2005; Garvey et al., 2009). GeneNetwork (Fehrmann
et al., 2015) (http://129.125.135.180:8080/GeneNetwork/) shows
that both ERCC1 and CD3EAP are expressed in tissues that
may be related to obstruction of the upper airway or diseases
of tissues/organs associated with OSA, such as muscle cells,
cartilage, trachea, salivary glands, heart and heart ventricles,
glucagon secreting cells, the neck and the tongue. This further
supports that ERCC1 and CD3EAP are interesting candidate
genes for symptoms of sleep apnea.
Rs2229918 is located on chromosome 19q13, a previously
identified region with suggestive evidence for linkage to OSA
in European-Americans, independently of BMI (Palmer et al.,
2003). Although APOE, a known candidate gene for OSA, is
also located in this region, it did not show association with OSA
in the present study. A previous study fine-mapped the APOE
region and concluded that APOE does not explain the linkage
signal, suggesting that APOE is not the causative locus (Larkin
et al., 2006). Although the linkage analysis performed by Palmer
et al. (2003) was redone by adding additional familymembers and
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TABLE 4 | Replication results, filtered on p < 1.0 × 10−6.
Marker name Gene Meta-analysis (N = 1475) Replication FHS (N = 472) Meta-analysis (discovery and replication,
N = 1947)
MAF Beta† SE p-value MAF Beta† SE p-value MAF Beta† SE p-value
rs137910205 ACE 0.001 2.56 0.46 3.15 × 10−08 – – – – – – – –
rs77091298 LIPJ 0.001 1.76 0.33 8.04 × 10−08 – – – – – – – –
rs9735156 MUC2 0.001 1.94 0.37 1.16 × 10−07 0.002 −0.14 0.34 0.69 0.001 0.83 0.25 9.09 × 10−04
11:977099 AP2A2 0.001 2.45 0.46 1.27 × 10−07 – – – – – – – –
rs149928566 SH3BP1 0.004 0.97 0.19 2.04 × 10−07 0.010 −0.16 0.16 0.33 0.005 0.33 0.12 7.69 × 10−03
rs117057052 KANK2 0.001 1.85 0.37 4.78 × 10−07 0.005 −0.12 0.22 0.59 0.002 0.39 0.19 3.66 × 10−02
9:139642861 LCN6 0.002 1.36 0.27 5.31 × 10−07 – – – – – – – –
rs148461790 TRAF3 0.001 2.30 0.46 6.83 × 10−07 – – – – – – – –
rs34515106 PLEK 0.001 1.64 0.33 6.87 × 10−07 – – – – – – – –
rs149348765 HIF1A 0.004 1.02 0.21 7.89 × 10−07 0.002 –0.15 0.34 0.66 0.004 0.71 0.18 6.09 × 10−05
rs139592793 SLC45A3 0.001 1.71 0.35 8.80 × 10−07 0.002 –0.27 0.34 0.43 0.002 0.70 0.24 3.91 × 10−03
rs2229918 ERCC1, CD3EAP 0.003 1.07 0.22 8.98 × 10−07 0.003 0.87 0.28 1.84 × 10−03 0.003 0.99 0.17 6.98 × 10−09
rs191846883 MRGPRE 0.003 0.96 0.20 9.61 × 10−07 – – – – – – – –
22:47058906 GRAMD4 0.001 1.92 0.39 9.78 × 10−07 – – – – – – – –
2:200803697 TYW5 0.001 2.27 0.46 9.83 × 10−07 – – – – – – – –
rs142729279 CST5 0.001 2.27 0.46 9.89 × 10−07 0.002 −0.02 0.34 0.95 0.001 0.78 0.28 4.35 × 10−03
MAF, Minor Allele Frequency; SE, Standard Error; –, Not available; FHS, Framingham Heart Study. †All effects are reported for the minor allele.
families, the chromosome 19 regionwas not confirmed. However,
this could be due to the genetic or disease heterogeneity (Larkin
et al., 2008).
Additionally, there were six rare variants (MAF < 0.4%) that
surpassed the Bonferroni corrected p-value threshold, of which
three (located in ACE, LIPJ and AP2A2) were monomorphic in
the FHS and could not be tested for replication. Our top finding,
rs137910205, a synonymous variant, is located in the ACE
(angiotensin converting enzyme) gene, one of the most studied
genes for OSA. Previous studies found an association between
the ACE insertion/deletion polymorphism and an increased risk
of hypertension in OSA patients (Lin et al., 2004; Bostrom
et al., 2007), although results are conflicting (Patel et al., 2007).
Further, plasma activity of ACE has been found to be increased
in untreated OSA patients (Barcelo et al., 2001). Both carriers
of rs137910205 (1 in each cohort) reported the highest score for
symptoms of sleep apnea, i.e. these individuals have experienced
pauses in breathing at least twice per week. The second variant
is the missense variant, rs77091298, located in the LIPJ (Lipase
Family Member J) gene. GeneNetwork showed that LIPJ is
expressed in the nasopharynx, neck, and muscle cells, all highly
relevant tissues in the pathogenesis of OSA (Fehrmann et al.,
2015). The third variant that could not be tested for replication,
11:977099, has not been identified before. The variant is located
in the AP2A2 gene (Adaptor Related Protein Complex 2 Alpha
2 Subunit), which is related to lipid binding (Stelzer et al., 2016).
However, we caution against the interpretation of statistics when
the number of carriers of the genetic variants is less than five.
Larger sample sizes are needed to further investigate the possible
association of these rare genetic variants with OSA.
This study has some limitations regarding the study design.
We have used questionnaire data for the assessment of symptoms
of sleep apnea, which could introduce bias (Fedson et al.,
2012). Although reports of breathing pauses more than twice
per week are highly predictive of polysomnographic sleep
apnea, self- or partner-reported breathing pauses have low
sensitivity (Young et al., 2002b). Individuals with sleep apnea
who experience predominantly hypopneas (shallow breathing)
rather than apneas may be less likely to be identified with
questionnaire data, as these individuals and their partners may
be less likely to recognize these events. Another limitation of
using questionnaire data is that the discrimination between
OSA, central sleep apnea and mixed sleep apnea is not possible.
Although the prevalence of central sleep apnea is generally much
lower than OSA in particular in general population samples
(Donovan and Kapur, 2016). Another limitation is that our
findings might not be generalizable to other populations as all
studies used in this analysis are predominantly European or
European American populations. Previous studies have shown
a difference in prevalence of sleep apnea between populations,
where young African Americans may be at increased risk
for sleep apnea (Redline et al., 1997) and had a higher
apnea-hypopnea index relative to European Americans with
OSA/hypopnea syndrome (Pranathiageswaran et al., 2013). The
frequency of the rs2229918 minor allele (G), based on the 1000
Genomes data, also differs across populations (https://www.ncbi.
nlm.nih.gov/variation/tools/1000genomes/). Lastly, sleep apnea
is a complex and heterogeneous disease influenced by many risk
factors such as obesity, age, gender (Redline et al., 1994; Bixler
et al., 2001; Young et al., 2002b,a, 2004; Peppard et al., 2013),
craniofacial and upper airway abnormalities (Mayer et al., 1996;
White, 2005), race (Redline et al., 1997; Li et al., 2000), alcohol
intake (Young et al., 2002a), smoking (Wetter et al., 1994),
and reduced nasal patency due to congestion and respiratory
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FIGURE 3 | Regional association plot for rs2229918. Rs2229918 is located in purple. The dots show the variants tested in this region on chromosome 19. The
−log10 transformed p-values are plotted on the y-axis and the genes and positions of the variants (Mb) in this region are depicted on the x-axis.
allergies (Young et al., 1997). Despite this phenotypic complexity,
we have identified and replicated a rare variant associated
with symptoms of sleep apnea. However, we have only used
one replication sample and additional studies should further
investigate the association of rs2229918 with sleep apnea using
objective measurements.
To conclude, this first meta-analysis of symptoms of sleep
apnea using WES data identified a rare genetic variant,
rs2229918 (MAF 0.3%), located in the 3′-UTR of ERCC1
and CD3EAP, associated with symptoms of sleep apnea.
Both genes are interesting candidate genes for (symptoms
of) sleep apnea based on their function and expression in
tissues relevant for the pathogenesis of the disease. However,
the involvement of rs2229918 in OSA pathology should
be further examined in larger datasets with more objective
measurements.
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